An observational study in Type 2 Diabetes Mellitus and Vascular Complications, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diabetes Mellitus, Type 2 by Assiut University — 15 open to participants now, 15 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Assiut University.
Among the 25 studies in Diabetes Mellitus, Type 2 by Assiut University, this one is the 12th largest by planned enrollment of the 23 observational ones that give a count, is one of 10 that started in 2026, is one of 23 observational ones, reaches primary completion later than 6 of the 14 other live ones, and was the 21st registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 25 studies in Diabetes Mellitus, Type 2 by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 18+
Assiut University · Sites in Egypt
Ages 18+ · Healthy volunteers
Assiut University
Ages 18–80
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 300 across 1,742 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 346 across the 2 interventional studies, 100 across the 23 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
7 of the studies in Diabetes Mellitus, Type 2 by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363122Assiut UniversityPlatelet Changes in Type 2 Diabetes | 2027-02 |
| NCT07773467Assiut UniversitySystemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease | 2027-09 |
| NCT07847099Assiut UniversityPlatelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications | 2027-09-26 |
| NCT07847112Assiut UniversitySoluble TREM-1 in Diabetes-Associated Cardiovascular Complications | 2027-10 |
| NCT07476248Assiut UniversityThe Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus | 2027-10-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 25 studies in Diabetes Mellitus, Type 2 by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.
Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.
This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.
Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications.
Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications.
Mean platelet volume in patients with and without vascular complications
Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.
Time frame: Baseline
Mean platelet distribution width
Mean platelet distribution width (PDW) compared between patients with and without vascular complications.
Time frame: Baseline
Distribution of ABO blood groups according to vascular complications
Frequency and percentage of ABO blood groups in patients with and without vascular complications.
Time frame: Baseline
Mean platelet volume according to ABO blood group
Mean platelet volume (MPV) among different ABO blood groups.
Time frame: Baseline
Prevalence of microvascular complications
Proportion of patients with microvascular complications (retinopathy, nephropathy, or neuropathy).
Time frame: Baseline
Prevalence of macrovascular complications
Proportion of patients with macrovascular complications (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.